Transfusion related acute lung injury (TRALI) prevention – selection of donors for producing plasma designated for clinical use

Czech version

Authors: V. Řeháček
Authors‘ workplace: Transfuzní oddělení, LF UK a FN Hradec Králové
Published in: Transfuze Hematol. dnes,27, 2021, No. 2, p. 154-158.
Category: Original Papers
doi: https://doi.org/10.48095/cctahd2021154

Overview

Transfusion related acute lung injury (TRALI) is a life-threatening complication of transfusions characterized by the development of acute respiratory distress occurring within 6 h following a blood transfusion. Leukocyte alloantibodies in the plasma of the transfused blood products and patient leukocytes play a leading role in the pathogenesis of TRALI. Reduction of TRALI risk is possible by implementing donor selection and by processing blood components. The objective of this study was to quantify the implementation of TRALI reduction interventions in the Czech Republic in 2019. The questionnaire sent out was completed by 51 blood banks (100%). Plasma for clinical use was produced by 47 blood banks (BB) in 2019. 37 BB (78.7%) implemented strategies to reduce the incidence of TRALI from their plasma blood components. 17 BB provided plasma from male donors without a history of transfusions, 13 BB used plasma from male donors without a history of transfusions and female donors without a history of pregnancy and transfusions, 7 BB used plasma from male donors, but did not determine their transfusion history. 5 BB performed additional testing of leukocyte antibodies. 10 BB did not perform any interventions to reduce TRALI risk. For 5 BB, the implementation of interventions would be complicated due to shortage of plasma products, logistical requirements, storage facilities, computer system modifications, risk of plasma deterioration and more expensive production. From 2012 to 2019, the number of BB that introduced the TRALI risk reduction policy increased from 24 to 37. The proportion of TRALI safe plasma has risen from 50% to more than 75%. Due to the occurrence of serious TRALI reactions in the Czech Republic between 2014–2019, further preventive measures are desirable.

Keywords:

TRALI – blood bank – transfusion – plasma – donor selection – risk prevention

Sources

1. Vlaar AP, Caulfield T, Chan P, et al. A consensus redefinition of transfusion-related acute lung injury. Transfusion. 2019;59:2465–2476.

2. Semple JW, Rebetz J, Kapur R. Transfusion-associated circulatory overload and transfusion-related acute lung injury. Blood. 2019;133(17):1840–1853.

3. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion. 2004;44:1774–1789.

4. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25:573–577.

5. Wallis JP, Sachs UJH. Transfusion-related acute lung injury. In: Simon TL, Snyder EL, Solheim BG. Plasma-induced TRALI is avoided with solvent/ detergent-treated plasma (abstract). Transfus Alternat Transfus Med. 2005 ;7(suppl):57.

6. Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA. 2002;287:1968–1971.

7. Middelburg RA, van Stein D, Briët E, van der Bom JG. The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systematic review. Transfusion. 2008;48:2167–2176.

8. Silliman CC, McLaughlin NJ. Transfusion-related acute lung injury. Blood Rev. 2006;20: 139–159.

9. Procházková R, Turek P. Potransfuzní reakce. In: Řeháček V, Masopust J, et al. Transfuzní lékařství. 1. vyd. Praha, Grada Publishing 2013;105–118.

10. Toy P, Bacchetti P, Grimes B, et al. Recipient clinical risk factors predominate in possible transfusion-related acute lung injury. Transfusion. 2015;55:947–952.

11. Výroční zprávy SÚKL 2014–2019. [online].Dostupné z: https:/ / www.sukl.cz/ sukl/ vyrocni-zprava-o-cinnosti-sukl.

12. Chapman CE, Williamson LM. National Blood Service TRALI reduction policies: implementation and effect. Transfus Med Hemother. 2008;35:93–96.

13. Chapman CE, Stainsby D, Jones H, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion. 2009;49:440–445.

14. Čermáková Z, Šimetka O, Kořístka M. Transfusion-related acute lung injury (TRALI) – review. Ceska Gynekol. 2013;78:211–215.

15. Seznam zařízení transfuzní služby, kterým byla povolena výroba transfuzních přípravků a surovin pro další výrobu. [online]. Dostupné z: http:/ / www.sukl.cz/ prehled-zarizeni-transfuzni-sluzby.

16. Řeháček V. Prevence TRALI – výběr dárců pro přípravu plazmy pro klinické použití – stav v ČR v roce 2012. Sborník abstrakt, 14. Pracovní dny v transfuzním lékařství Liberec 2013;43.

17. Brittingham TE. Immunologic studies on leukocytes. Vox Sang. 1957;2:242–248.

18. Popovsky MA, Haley NR. Further characterization of transfusion-related acute lung injury: demographics, clinical and laboratory features, and morbidity. Immunohaematology. 2000;16:157–159.

19. Middelburg RA, Porcelijn L, Lardy N, Briët E, Vrielink H. Prevalence of leucocyte antibodies in the Dutch donor population. Vox Sang. 2011;100:327–335.

20. van Stein D, Beckers EA, Sintnicolaas K, et al. Transfusion-related acute lung injury reports in the Netherlands: an observational study. Transfusion. 2010;50:213–220.

21. Win N, Massey E, Lucas G, et al. Ninety-six suspected transfusion related acute lung injury cases: investigation findings and clinical outcome. Hematology. 2007;12:461–469.

22. Densmore TL, Goodnough LT, Ali S, Dynis M, Chaplin H. Prevalence of HLA sensitization in female apheresis donors. Transfusion. 1999;39:103–106.

23. Fadeyi EA, De Los Angeles Muniz M, Wayne AS, Klein HG, Leitman SF, Stroncek DF. The transfusion of neutrophil-specific antibodies causes leukopenia and a broad spectrum of pulmonary reactions. Transfusion. 2007;47:545–550.

24. Gajic O, Yilmaz M, Iscimen R, et al. Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components. Crit Care Med. 2007;35:1645–1648.

25. Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood. 2012;119:1757–1760.

26. Middelburg RA, Van Stein D, Zupanska B, et al. Female donors and transfusion-related acute lung injury: A case-referent study from the International TRALI Unisex Research Group. Transfusion. 2010;50:2447–2454.

27. Čermáková Z, Kořístka M, Blahutová Š, et al. Transfusion-related acute lung injury: report of two cases. Prague Med Rep. 2012;113:294–298.

28. Reesing HW, Engelfriet CP, editors. International forum: measures to prevent TRALI. Vox Sang. 2007;92:258–277.

29. Eder AF, Herron RM Jr, Strupp A, et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006–2008). Transfusion. 2010;50:1732–1742.

30. Wiersum-Osselton JC, Middelburg RA, Beckers EA, et al. Male-only fresh-frozen plasma for transfusion-related acute lung injury prevention: before-and-after comparative cohort study. Transfusion. 2011;51:1278–1283.

31. Insunza A, Romon I, Gonzalez-Ponte ML, et al. Implementation of a strategy to prevent TRALI in a regional blood centre. Transfus Med. 2004;14:157–164.

32. Middelburg RA, Beckers EA, Porcelijn L, et al. Allo-exposure status and leucocyte antibody positivity of blood donors show a similar relation with TRALI. Transfus Med. 2012;22:128–132.

33. Sachs UJ, Kauschat D, Bein G. White blood cell-reactive antibodies are undetectable in solvent/ detergent plasma. Transfusion. 2005;45:1628–1631.

34. Solheim BG, Stowell CP, Strauss RG, Petrides M. Rossis‘s principles of transfusion medicine. 4. vyd. West Sussex, UK, John Wiley & Sons Ltd; Bethesda, USA, AABB press, 2009;870–884.

35. Saadah NH, van Hout FM, Schipperus MR, et al. Comparing transfusion reaction rates for various plasma types: a systematic review and meta-analysis/ regression. Transfusion. 2017;57:2104–2114.